STAAR Surgical (NASDAQ:STAA) Posts Earnings Results, Misses Expectations By $0.12 EPS

STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12), Briefing.com reports. The company had revenue of $77.40 million for the quarter, compared to analysts’ expectations of $75.34 million. STAAR Surgical had a return on equity of 8.73% and a net margin of 6.62%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.05 EPS.

STAAR Surgical Stock Performance

STAA traded up $0.67 on Tuesday, reaching $46.65. 724,669 shares of the company’s stock were exchanged, compared to its average volume of 725,793. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $68.27. The company’s 50 day moving average is $41.66 and its 200-day moving average is $35.80. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 108.49 and a beta of 0.80.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, Director Aimee S. Weisner bought 1,750 shares of STAAR Surgical stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average price of $38.11 per share, for a total transaction of $66,692.50. Following the acquisition, the director now owns 10,864 shares of the company’s stock, valued at approximately $414,027.04. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of STAAR Surgical from $32.00 to $46.00 and gave the stock a “hold” rating in a research report on Monday, April 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, April 4th. Piper Sandler reduced their target price on STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Stifel Nicolaus restated a “buy” rating and issued a $50.00 price target on shares of STAAR Surgical in a report on Monday, April 1st. Finally, William Blair upgraded shares of STAAR Surgical from a “market perform” rating to an “outperform” rating in a report on Thursday, April 4th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, STAAR Surgical has an average rating of “Hold” and a consensus target price of $46.38.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.